Alex Rodriguez TRT: How the Media Narrative Shifted

The Biogenesis Scandal: What Rodriguez Actually Used

The 2013 Biogenesis investigation revealed that Rodriguez received testosterone and human growth hormone from Anthony Bosch's Florida clinic, not a physician. MLB suspended him for 211 games under the Joint Drug Prevention and Treatment Program, later reduced to 162 games on appeal, making it the longest non-lifetime suspension in the sport's history.

What the Clinic Was Providing

Bosch's operation supplied what he called "troches," sublingual testosterone lozenges, alongside injectable testosterone preparations and peptide compounds. These were not prescribed through any licensed medical channel. The distinction matters clinically: exogenous testosterone administered outside a physician-supervised protocol carries measurably different risk profiles than TRT monitored with periodic CBC, lipid panels, and PSA screening.

The World Anti-Doping Agency flags a urinary testosterone-to-epitestosterone (T/E) ratio above 4:1 as presumptive evidence of exogenous testosterone use. Natural male T/E ratios cluster between 1:1 and 2:1. Rodriguez never formally contested the substance findings; his legal challenge targeted procedural grounds.

Growth Hormone: A Separate Compound

Human growth hormone (hGH) was listed separately in Biogenesis records. Recombinant hGH is detectable via serum IGF-1 elevation and isoform assays. The FDA has approved hGH only for specific adult indications, including adult growth hormone deficiency confirmed by stimulation testing. Off-label athletic use is not an approved indication and carries risks including acromegalic changes, insulin resistance, and carpal tunnel syndrome. Studies have found that supraphysiologic GH administration raises IGF-1 to levels associated with increased cancer risk in observational cohorts.

How WADA and MLB Testing Differ From Clinical TRT Monitoring

Anti-doping testing and clinical TRT monitoring use different tools for different purposes. Understanding this distinction is central to why the same molecule, testosterone, carries radically different social meanings depending on context.

Anti-Doping Detection

WADA's Prohibited List bans exogenous androgens in-competition and out-of-competition for all athletes. Detection relies on the T/E ratio, the carbon isotope ratio (CIR) test (which distinguishes synthetic from endogenous testosterone by its ¹³C/¹²C signature), and longitudinal Athlete Biological Passport (ABP) profiling. The CIR test has a sensitivity of approximately 95% for detecting synthetic testosterone when T/E exceeds 4:1.

MLB adopted its current Joint Drug Prevention and Treatment Program in 2002 and has tightened thresholds repeatedly. Athletes with genuine hypogonadism may apply for a Therapeutic Use Exemption (TUE), but the bar is high: documented morning serum testosterone below the laboratory reference range on two separate draws, plus clinical symptoms.

Clinical TRT Monitoring

A physician managing legitimate TRT orders morning total testosterone (drawn 7 to 10 days after the last injection to avoid peak), hematocrit, PSA, and lipid panel at baseline and then every 3 to 6 months. The Endocrine Society Clinical Practice Guideline recommends testosterone therapy for men with symptomatic hypogonadism and two morning serum testosterone levels consistently below 300 ng/dL, confirmed by a reliable assay. The goal is to restore mid-normal physiologic levels (400 to 700 ng/dL), not supraphysiologic concentrations used in performance settings.

The Clinical Reality of Age-Related Testosterone Decline

Male testosterone levels decline at roughly 1 to 2% per year after age 30. A cross-sectional analysis of the European Male Ageing Study (N=3,369) found that 17.0% of men aged 40 to 79 had biochemical hypogonadism defined as total testosterone below 11 nmol/L (approximately 317 ng/dL). Rodriguez was born in 1975, meaning by his mid-40s he fell squarely into the age window where symptomatic hypogonadism becomes statistically common.

Symptoms That Drive Men to Seek TRT

The Endocrine Society identifies the following as the most specific symptoms of hypogonadism: reduced libido, erectile dysfunction, decreased spontaneous erections, infertility, loss of body or facial hair, gynecomastia, and, in severe cases, hot flushes. Less specific symptoms include fatigue, depressed mood, poor concentration, reduced muscle mass, and increased adiposity. A man presenting with only the non-specific cluster may not meet criteria for TRT even with a borderline testosterone level.

What the Numbers Actually Mean

Total testosterone is the standard first-line test, but free testosterone (the biologically active fraction) matters in men with obesity, because sex hormone-binding globulin (SHBG) levels vary. Research published in JCEM found that calculated free testosterone identified an additional 15% of men as hypogonadal who had normal total testosterone, particularly those with elevated SHBG from aging or metabolic disease. Rodriguez, who has publicly discussed weight management, would fit the profile where both measurements are clinically relevant.

A Standard TRT Protocol in 2025

The following reflects current prescribing practice under Endocrine Society and American Urological Association guidance. No document suggests this was Rodriguez's personal protocol; it represents what a board-certified endocrinologist or urologist would prescribe for a symptomatic male with confirmed hypogonadism in his late 40s.

Injectable Testosterone

Testosterone cypionate 100 mg intramuscularly every week (or 200 mg every two weeks) remains the most common US formulation due to cost and availability. FDA-approved testosterone cypionate carries a black-box warning regarding secondary exposure in children and thromboembolic events. Weekly injections produce more stable serum levels than biweekly dosing, reducing the peak-and-trough symptom swings that some patients report. A randomized trial in JCEM (N=234) confirmed that weekly testosterone undecanoate injections produced steadier T levels than 10-week depot injections over a 52-week period.

Transdermal Options

Testosterone gel (AndroGel 1.62%, 20.25 to 81 mg/day; Testim 50 to 100 mg/day) applied to the shoulders or upper arms produces less dramatic peaks. In a phase III trial (N=274), testosterone gel 1.62% normalized serum testosterone in 77% of hypogonadal men at 16 weeks. The transfer risk to partners or children requires strict handwashing or covering the application site. Nasal testosterone gel (Natesto 11 mg TID) avoids transfer and has less suppressive effect on spermatogenesis, an advantage for men who may want to preserve fertility. Data from a 90-day trial showed Natesto maintained sperm concentration above 15 million/mL in 92% of participants, compared to near-universal azoospermia with standard injectable TRT.

Subcutaneous Pellets

Testosterone pellets (Testopel, 150 to 450 mg implanted every 3 to 6 months) offer convenience but cannot be removed if side effects emerge. Hematocrit elevation is the most common laboratory concern with any TRT formulation. The Endocrine Society guideline specifies withholding TRT if hematocrit exceeds 54% due to hyperviscosity risk.

Managing Estradiol and Fertility

Aromatase converts testosterone to estradiol. Supraphysiologic T drives estradiol above 40 to 50 pg/mL in some men, causing gynecomastia or water retention. Anastrozole 0.5 mg twice weekly is used off-label to blunt this conversion, though a Cochrane review cautioned that routine aromatase inhibitor use in TRT-treated men lacks long-term safety data. For men concerned about fertility, human chorionic gonadotropin (hCG) 500 IU three times weekly co-administered with TRT has been shown to maintain intratesticular testosterone and sperm production.

The Media Narrative Shift: From Cheater to Patient

Phase 1: The Scandal Frame (2009 to 2015)

Rodriguez first admitted to steroid use in 2009, acknowledging testosterone use from 2001 to 2003 while with the Texas Rangers. His 2013 Biogenesis suspension followed. Coverage during this period used the frame of elite athlete cheating: betrayal of teammates, fans, and competitive fairness. The clinical dimension received almost no coverage. Research on media framing of doping cases shows that sports journalists consistently emphasize moral failure over physiological context, a pattern that shapes public perception independent of the underlying biology.

Phase 2: Retirement and Reframing (2019 to 2022)

After retiring from playing in 2016 and transitioning to broadcasting and entrepreneurship, Rodriguez began appearing in media contexts where wellness, biohacking, and hormone optimization were normalized topics. Podcasts, men's health platforms, and financial media increasingly treated middle-aged men's testosterone management as routine health maintenance rather than athletic fraud.

This shift tracked a broader cultural change. Google Trends data and survey research published in Translational Andrology and Urology found that TRT prescriptions in the United States increased by 500% between 2000 and 2011, and the normalization has continued through telehealth expansion. By 2021, direct-to-consumer TRT platforms were advertising on mainstream sports media, making Rodriguez's history easier for audiences to reinterpret through a health lens.

Phase 3: The Wellness Celebrity Template (2022, Present)

By 2022, Rodriguez was openly discussing health optimization, diet, and fitness in interviews without any sports context. The questions from interviewers shifted from "did you cheat?" to "how do you stay in shape at 47?" This template, where a former PED-linked athlete becomes a wellness authority, has precedent. Public health researchers have noted that celebrity health narratives carry disproportionate influence on lay health decisions, particularly when the celebrity has already been through a visible transformation story.

The danger in this reframe is uncritical adoption. Rodriguez's Biogenesis-era use was supraphysiologic, unmonitored, and obtained outside any medical relationship. Legitimate TRT is none of those things.

Cardiovascular and Hematologic Risks: What the Evidence Shows

Cardiovascular Signal

The cardiovascular safety of TRT remains an active research question. The TRAVERSE trial (N=5,246), published in NEJM in 2023, found that testosterone replacement in middle-aged and older men with hypogonadism and pre-existing cardiovascular disease or high CV risk did not increase the rate of major adverse cardiovascular events (MACE) at a median follow-up of 33 months. This was a landmark finding that shifted prescribing confidence. The trial did find a higher rate of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone group, findings that warrant ongoing monitoring even under guideline-concordant TRT.

Polycythemia

Hematocrit elevation above 54% occurred in 5.7% of the testosterone group in TRAVERSE vs. 1.5% placebo. Elevated hematocrit raises whole-blood viscosity and thrombotic risk, a mechanism documented in both observational and experimental data. Therapeutic phlebotomy or dose reduction are standard responses. Any TRT patient should have hematocrit checked at 3 and 6 months, then annually.

Prostate Safety

A meta-analysis of 22 randomized controlled trials (N=2,351) published in JAMA found no statistically significant increase in prostate cancer incidence with TRT, though follow-up periods were generally under 3 years. PSA monitoring every 6 to 12 months remains standard practice. TRT is contraindicated in men with untreated prostate cancer or a PSA above 4 ng/mL without urology clearance.

Why the Distinction Between PED Use and TRT Matters Clinically

Untreated hypogonadism carries real consequences. A longitudinal study of 794 men followed for 10 years found that low testosterone was independently associated with a 40% higher all-cause mortality rate, after adjusting for age, BMI, and comorbidities. Bone mineral density falls measurably in hypogonadal men; a trial published in NEJM showed that testosterone therapy in older men with low testosterone increased volumetric bone density by 7.5% at the spine over 12 months.

The Rodriguez story has inadvertently pushed more men toward conversations with their physicians about fatigue, libido changes, and body composition. That outcome, if it leads to proper diagnostic workup, is medically net-positive. The risk is the other direction: men self-administering testosterone purchased through gray-market channels, following the celebrity performance dose rather than the clinical replacement dose.

The FDA's MedWatch database documents adverse events from non-prescribed androgen use including polycythemia, stroke, and cardiac arrhythmia, none of which appear in athletes' wellness rebranding narratives.

As the Endocrine Society's 2018 Clinical Practice Guideline states directly: "We recommend against starting testosterone therapy in patients with the intention of preserving or improving fertility." The therapeutic goal is symptom resolution at physiologic concentrations, not performance optimization.